Innoviva Inc. Stock
Innoviva Inc. Stock
Innoviva Inc. shows a slight decrease today, losing -€0.100 (-0.560%) compared to yesterday.
Innoviva Inc. is currently one of the favorites of our community with 10 Buy predictions and no Sell predictions.
Based on the current price of 17.9 € the target price of 36 € shows a potential of 101.12% for Innoviva Inc. which would more than double the current price.
Pros and Cons of Innoviva Inc. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Innoviva Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Innoviva Inc. | -0.560% | -3.209% | -6.701% | 13.836% | 10.366% | 53.390% | 44.800% |
| Pacira Pharmaceuticals | 0.860% | -1.724% | 2.703% | 21.925% | 5.556% | -34.483% | -54.400% |
| Corcept Therapeutics Inc. | -1.800% | 22.242% | 25.500% | 64.219% | 43.229% | 242.448% | 438.132% |
| Supernus Pharmaceuticals | 14.510% | -3.500% | -7.656% | 26.974% | -10.233% | 33.103% | 70.796% |
Comments
Innoviva (INVA) had its "buy" rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (INVA) had its "buy" rating reaffirmed by HC Wainwright. They now have a $46.00 price target on the stock.
Show more
Ratings data for INVA provided by MarketBeat
Innoviva (INVA) had its "buy" rating reaffirmed by BTIG Research. They now have a $42.00 price target on the stock.
Show more
Ratings data for INVA provided by MarketBeat
News
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Dauntless Investment Group disclosed in a May 14, 2026, SEC filing that it bought 116,863 shares of Innoviva (NASDAQ:INVA), an estimated $2.52 million trade based on quarterly average pricing.
